<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000819'>Diabetes mellitus</z:hpo> is a major public health problem, in particular because of long-term complications affecting essential organs, such as the eyes and kidneys, which can lead to a reduction in life expectancy and high healthcare costs </plain></SENT>
<SENT sid="1" pm="."><plain>The number of individuals with <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is projected to rise worldwide from 171 million people in 2000 to 366 million people in 2030 </plain></SENT>
<SENT sid="2" pm="."><plain>With the number of patients with <z:mp ids='MP_0002055'>diabetes</z:mp> continually growing, the burden of pressure on worldwide health systems is huge </plain></SENT>
<SENT sid="3" pm="."><plain>Accordingly, regulatory and marketing approvals of new medicines are beginning to incorporate economic evaluation techniques to determine their cost-effectiveness </plain></SENT>
<SENT sid="4" pm="."><plain>Overall, the studies included in this review show that the initiation of insulin glargine is cost-effective and is expected to lead to substantial improvements in both life years (LYs) and quality-adjusted LYs compared with neutral protamine Hagedorn insulin </plain></SENT>
</text></document>